Last reviewed · How we verify
URAPIDIL (EUPRESSYL*)
Urapidil is a selective and competitive antagonist of the 5-HT1A receptor.
Urapidil is a selective and competitive antagonist of the 5-HT1A receptor. Used for Hypertension.
At a glance
| Generic name | URAPIDIL (EUPRESSYL*) |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | 5-HT1A receptor antagonist |
| Target | 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the 5-HT1A receptor, urapidil reduces the vasoconstrictive effects of serotonin, leading to vasodilation and a decrease in blood pressure. This mechanism is thought to contribute to its antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
Key clinical trials
- The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine (PHASE3)
- Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |